EOFlow has teamed up with Diabeloop, a medical device company focused on automated diabetes treatment solutions, to provide patients with easy access to EOFlow’s EOPatch system powered by automated insulin delivery (AID) algorithm from Diabeloop.

The partnership will create an AID system that combines EOFlow’s wearable insulin pump EOPatch, and a third-party CGM device, with Diabeloop’s smartphone app-based, integrated AID algorithm.

In addition, the companies intend to integrate the EOPatch insulin pump into Diabeloop’s DBLG1 System, to access the algorithm in a dedicated handset.

Diabeloop said that its DBLG1 algorithm and EOFlow’s EOPatch and the third-party CGM, all have received CE mark approvals.

The integrated AID system could be offered to patients after the completion of its development, with a commercial launch in Europe expected by the end of this year.

Diabeloop co-founder and CEO Erik Huneker said: “It is an honour to partner with EOFlow and combine our state-of-the-art automated insulin delivery algorithm with their innovative wearable insulin pump solution.

“Diabeloop and EOFlow share the same goal to offer choices to people living with diabetes by providing advanced and user-friendly solutions.

“We confirmed the technical feasibility of our integration through a Hackathon last summer, and we are expanding this as an official development agreement to commercialise a combined solution.”

In line with its interoperable strategy, Diabeloop is currently in talks with several medical device manufacturers and is developing its smartphone app.

The current partnership with EOFlow, which offers EOPatch, a disposable, tubeless insulin pump solution, is expected to address the patient’s need for wearable solutions.

EOFlow has rolled out EOPatch in South Korea and Europe, under GlucoMen Day brand, through its European partner A. Menarini Diagnostics.

EOPatch is offered with a smartphone application, dubbed Narsha, which is registered on Google Play Store and Apple AppStore.

EOFlow founder and CEO Jesse J Kim said: “In the field of automated insulin delivery, the adaptability and scalability of our wearable insulin pump is limitless, and we are working toward placing ourselves in a leadership position.

“While we continue to commercialise EOPatch X, our artificial pancreas solution, we’re excited to kick off this partnership with Diabeloop and bring a wearable AID option to users sooner. We are also eager to make the smartphone app available in the European market.”